scholarly journals Extracorporeal Shock Wave Therapy Combined with Complex Decongestive Therapy in Patients with Breast Cancer-Related Lymphedema: A Systemic Review and Meta-Analysis

2021 ◽  
Vol 10 (24) ◽  
pp. 5970
Author(s):  
Yu Lin Tsai ◽  
Ting Jie I ◽  
Ya Chi Chuang ◽  
Yuan Yang Cheng ◽  
Yu Chun Lee
Keyword(s):  
Breast Cancer ◽  
Shock Wave ◽  
Meta Analysis ◽  
Extracorporeal Shock Wave Therapy ◽  
Systemic Review ◽  
Skin Thickness ◽  
Shock Wave Therapy ◽  
Complex Decongestive Therapy ◽  
Extracorporeal Shock Wave ◽  
Breast Cancer Related Lymphedema

Breast cancer-related lymphedema (BCRL) is one of the most significant complications seen after surgery. Several studies demonstrated that extracorporeal shock wave therapy (ESWT), in addition to conventional complex decongestive therapy (CDT), had a positive effect on BCRL in various aspects. The systematic review and meta-analysis aim to explore the effectiveness of ESWT with or without CDT on BRCL patients. We searched PubMed, Embase, PEDro, Cochrane Library Databases, and Google Scholar for eligible articles and used PRISMA2020 for paper selection. Included studies were assessed by the PEDro score, Modified Jadad scale, STROBE assessment, and GRADE framework for the risk of bias evaluation. The primary outcomes were the volume of lymphedema and arm circumference. Secondary outcome measures were skin thickness, shoulder joint range of motion (ROM), and an impact on quality-of-life questionnaire. Studies were meta-analyzed with the mean difference (MD). Eight studies were included in the systemic review and four in the meta-analysis. In summary, we found that adjunctive ESWT may significantly improve the volume of lymphedema (MD = −76.44; 95% CI: −93.21, −59.68; p < 0.00001), skin thickness (MD = −1.65; 95% CI: −3.27, −0.02; p = 0.05), and shoulder ROM (MD = 7.03; 95% CI: 4.42, 9.64; p < 0.00001). The evidence level was very low upon GRADE appraisal. ESWT combined with CDT could significantly improve the volume of lymphedema, skin thickness, and shoulder ROM in patients with BCRL. There is not enough evidence to support the use of ESWT as a replacement for CDT. This study was registered with PROSPERO: CRD42021277110.

scholarly journals THE EFFECTIVENESS OF EXTRACORPOREAL SHOCK WAVE THERAPY ON BREAST CANCER-RELATED LYMPHEDEMA: A LITERATURE REVIEW

Lymphology ◽  
2021 ◽  
Vol 53 (3) ◽  
Author(s):  
S Miccinilli ◽  
M Bravi ◽  
M Maselli ◽  
F Santacaterina ◽  
M Morrone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Shock Wave ◽  
Extracorporeal Shock Wave Therapy ◽  
Breast Cancer Surgery ◽  
Treatment Modalities ◽  
Cochrane Library ◽  
Shock Wave Therapy ◽  
High Quality Research ◽  
Extracorporeal Shock Wave ◽  
Breast Cancer Related Lymphedema

Lymphedema is one of the most dreaded complications related to breast cancer surgery, commonly resulting in upper limb functional, esthetic, and psychological impairment. The necessity to improve the efficacy of conventional treatments and the promising effect of extracorporeal shock wave therapy (ESWT) on lymphangiogenesis in vitro and animal models, has prompted studies involving women affected by breast-cancer related lymphedema. Since intervention modalities and treatment protocols used are different, a review is necessary to verify the effectiveness of ESWT, evaluating the quality of existing studies and the eventual need for further research. Data were obtained from PubMed, Scopus, Google Scholar, Cochrane Library and PEDro, including articles published until January 2019. Five studies met the inclusion criteria. Evident heterogeneity emerged among selected studies permitting only a purely descriptive analysis of their data and strongly limiting their comparison. When compared to other treatment modalities, ESWT showed a significant effect on measured outcomes. It is clear that further high quality research is necessary to assert with confidence the effects and possible superiority of ESWT over other conservative therapies in the management of breast-cancer related lymphedema.

Extracorporeal Shock Wave Therapy for Breast Cancer–Related Lymphedema: A Pilot Study

2016 ◽  
Vol 97 (9) ◽  
pp. 1520-1525 ◽  
Author(s):  
Mehtap Aykac Cebicci ◽  
Serap Tomruk Sutbeyaz ◽  
Sema Sezgin Goksu ◽  
Sehriban Hocaoglu ◽  
Arzu Oguz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Shock Wave ◽  
Pilot Study ◽  
Extracorporeal Shock Wave Therapy ◽  
Shock Wave Therapy ◽  
Extracorporeal Shock Wave ◽  
Breast Cancer Related Lymphedema

scholarly journals Extracorporeal shock wave therapy as a potential therapeutic tool for breast cancer related lymphedema: a narrative review of in vitro, animal and clinical studies

2021 ◽  
Vol 15 (1) ◽  
pp. 1-12
Author(s):  
Julia Konrad ◽  
Magdalena Grygiel
Keyword(s):  
Breast Cancer ◽  
Shock Wave ◽  
Clinical Trials ◽  
Animal Experiments ◽  
Extracorporeal Shock Wave Therapy ◽  
Shock Wave Therapy ◽  
Therapeutic Tool ◽  
Extracorporeal Shock Wave ◽  
Breast Cancer Related Lymphedema

Background: The treatment of breast cancer related lymphedema (BCRL) focuses on the alleviation symptoms. One of the innovative, non-invasive therapies used for this condition is extracorporeal shock wave therapy (ESWT). Aim of the study: To review the available literature and evaluate the effectiveness of ESWT in the treatment of secondary lymphedema (in vitro works, animal experiments) and lymphedema associated with the treatment of breast cancer. Material and methods: The scientific literature review was conducted from October to December 2020. The review was carried out by searching scientifically recognized medical databases, including PubMed, MEDLINE and PEDro. Date restrictions were not applied. As there are only a few clinical studies assessing the effectiveness of ESWT on the reduction of lymphedema, case reports, animal experiments and in vitro works were included in the review. Articles written in a language other than English were excluded. Results: In total, the analysis included twelve studies, including seven clinical trials, one case report, three animal experiments and one in vitro test. Conclusions: Based on the results of the analyzed articles, ESWT can be an effective therapeutic tool for lymphedema occurring after breast cancer treatment. Unfortunately, the level of evidence is relatively weak since the number of publications on this subject is still quite low. The accumulated results indicate the need for further clinical trials.

Sign in / Sign up

Export Citation Format

Share Document